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OBJECTIVES: Cigarette smoke (CS) is recognized as a major cause of cardiovascular disease 
(CVD). Inflammatory responses play important roles in the pathophysiological processes of CS-
induced cardiac damage. Mesenchymal stem cells (MSCs) are regarded as a promising candidate 
for cell-based therapy in CVD. We aimed to compare the effects of bone marrow-derived MSCs 
(BM-MSCs) and induced pluripotent stem cell-derived MSC (iPSC-MSCs) on cardiac function 
and inflammation in CS-exposed rat model. 
 
METHODS: Male Sprague-Dawley rats were exposed to 4% CS for one hour daily for 56 days. 
On day 29 and day 43, human iPSC-MSCs or adult bone marrow-MSCs (BM-MSCs) were 
administered intravenously to CS-exposed rats. Echocardiography was conducted 24h after the 
last exposure and animals were sacrificed. Heart tissues were collected for paraffin sectioning and 
protein extraction to determine levels of pro-/anti-inflammatory cytokines. 
 
RESULTS: iPSC-MSC-treated group had a greater effect in the improvement of CS-induced 
cardiac dysfunction, myocardial hypertrophy and interstitial fibrosis than BM-MSC-treated group. 
The CS-induced elevation of cardiac pro-inflammatory cytokines, tumor necrosis factor-alpha 
(TNF-α), cytokine-induced neutrophil chemoattractant-1 (CINC-1, resemble to human IL-8) and 
monocyte chemoattractant protein-1 (MCP-1) was attenuated by either iPSC-MSCs or BM-MSCs 
administration. However, CS-induced reduction of cardiac anti-inflammatory cytokines, 
interleukin-10 (IL-10) and adiponectin, was restored only by iPSC-MSCs administration. Both 
treatments reversed CS-induced reduction of cytoplasmic IκBα expression and nuclear 
translocation of nuclear factor-κB (NF-κB) p65 subunit. 
 
CONCLUSIONS: Our findings demonstrate a higher capacity of iPSC-MSCs than BM-MSCs to 
ameliorate CS-induced cardiac dysfunction and cardiac remodeling via NF-kB signaling pathway 
by inhibiting pro-inflammatory cytokines and restoring anti-inflammatory cytokines in CS-
exposed rat model. iPSC-MSCs may thus hold promise for the development of cell-based therapy 
in cardiac protection. 
